Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Landgren

Showing results (301-310 of 519) with videos related to

Pageof 52
Sort By:
Scientific Reports|October 18, 2019
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomidePhoebe A Huang, Shaunna L Beedie, Cindy H Chau, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Impact of rare structural variant events in newly diagnosed multiple myelomaMonika Chojnacka, Benjamin Diamond, Bachisio Ziccheddu, et al.
Investigational New Drugs|March 4, 2020
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myelomaEric K Rowinsky, Agne Paner, Jesus G Berdeja, et al.
JAMA Oncology|October 27, 2022
Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With CancerAngela K Green, Sara M Tabatabai, Carol Aghajanian, et al.
British Journal of Haematology|May 24, 2022
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR studyOla Landgren, Katja Weisel, Laura Rosinol, et al.
Leukemia|April 23, 2020
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myelomaHans C Lee, Noopur S Raje, Ola Landgren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2016
Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma PatientsS Peter Wu, Ruth M Pfeiffer, Inhye E Ahn, et al.
European Journal of Haematology|February 10, 2021
Comorbidities in multiple myeloma and implications on survival: A population-based studyIngigerður S Sverrisdóttir, Sölvi Rögnvaldsson, Sigrún Thorsteinsdottir, et al.
JCO Global Oncology|August 12, 2022
Global Myeloma Trial Participation and Drug Access in the Era of Novel TherapiesRaleigh Ayoolu Fatoki, Kelly Koehn, Amar Kelkar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008Magnus Björkholm, Lotta Ohm, Sandra Eloranta, et al.
Pageof 52

Showing results (301-310 of 519) with videos related to

Sort By:
Pageof 52
Scientific Reports|October 18, 2019
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomidePhoebe A Huang, Shaunna L Beedie, Cindy H Chau, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Impact of rare structural variant events in newly diagnosed multiple myelomaMonika Chojnacka, Benjamin Diamond, Bachisio Ziccheddu, et al.
Investigational New Drugs|March 4, 2020
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myelomaEric K Rowinsky, Agne Paner, Jesus G Berdeja, et al.
JAMA Oncology|October 27, 2022
Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With CancerAngela K Green, Sara M Tabatabai, Carol Aghajanian, et al.
British Journal of Haematology|May 24, 2022
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR studyOla Landgren, Katja Weisel, Laura Rosinol, et al.
Leukemia|April 23, 2020
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myelomaHans C Lee, Noopur S Raje, Ola Landgren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2016
Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma PatientsS Peter Wu, Ruth M Pfeiffer, Inhye E Ahn, et al.
European Journal of Haematology|February 10, 2021
Comorbidities in multiple myeloma and implications on survival: A population-based studyIngigerður S Sverrisdóttir, Sölvi Rögnvaldsson, Sigrún Thorsteinsdottir, et al.
JCO Global Oncology|August 12, 2022
Global Myeloma Trial Participation and Drug Access in the Era of Novel TherapiesRaleigh Ayoolu Fatoki, Kelly Koehn, Amar Kelkar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008Magnus Björkholm, Lotta Ohm, Sandra Eloranta, et al.
Pageof 52